Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective

Harmandeep Kaur Gill1, Parjeet Kaur1, Shama Mahendru1

  • 1Division of Endocrinology and Diabetes, Medanta The Medicity, Gurugram, Haryana, India.

Abstract

Insights

Sodium glucose co-transporter 2 inhibitors (SGLT2i) show comparable effectiveness for type 2 diabetes mellitus (T2DM) management in real-world Asian settings. However, adverse effects like genitourinary infections occurred more frequently than in clinical trials.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Sodium glucose co-transporter 2 inhibitors (SGLT2i) demonstrate efficacy in clinical trials for type 2 diabetes mellitus (T2DM).
  • Limited real-world data exists for SGLT2i use in Asian populations.

Purpose of the Study:

  • To assess the safety and effectiveness of SGLT2 inhibitors in a real-world setting for T2DM patients in Asia.
  • To compare real-world outcomes with findings from clinical trials.

Main Methods:

  • Prospective observational longitudinal study.
  • Consecutive T2DM patients initiated on SGLT2i between April 2015 and March 2016.
  • Adverse effects and metabolic parameters monitored at 3-month intervals for up to 1 year.

Main Results:

  • 486 patients initiated on SGLT2i; 388 had data at 6 months.
  • Adverse effects reported in 38.6% of patients, primarily genitourinary tract infections (20.6%) and generalized weakness (10.5%).
  • Significant reductions in HbA1c (1.26% at 6 months, 1.27% at 12 months) and weight (3.2 kg at 6 months, 3.9 kg at 12 months) were observed.

Conclusions:

  • SGLT2i use in T2DM patients in a hot climate was associated with a higher incidence of adverse effects compared to clinical trials.
  • The effectiveness of SGLT2i in terms of glycemic control and weight reduction was comparable to clinical trial findings.
  • Patient education on hydration and hygiene is crucial for maximizing SGLT2i benefits and mitigating risks.

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.3K
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
781
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
793
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
715
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
137.5K
Primary Active Transport01:47

Primary Active Transport

In contrast to passive transport, active transport involves a substance being moved through membranes in a direction against its concentration or electrochemical gradient. There are two types of active transport: primary active transport and secondary active transport. Primary active transport utilizes chemical energy from ATP to drive protein pumps that are embedded in the cell membrane. With energy from ATP, the pumps transport ions against their electrochemical gradients—a direction...
197.4K